2019 Outlook: Drug Competition Stays at Forefront of FDA Agenda

The FDA will keep charging forward on increasing drug product competition in the new year while also revamping its medical device approval process, FDA leader Scott Gottlieb told Bloomberg Law.

Gottlieb sat down recently with Bloomberg Law to discuss what officials at the Food and Drug Administration have in mind for 2019.

Generic drug approvals have hit record highs since Gottlieb took over as commissioner in May 2017. The thirst for more options, particularly cheaper options, has remained high since President Donald Trump released his drug pricing plan this summer.

Agency heads will continue to push forward on ...